Medical Tech Stock Aethlon Medical's (NASDAQ: AEMD) Australian Oncology Clinical Trial Update and Progress Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers SAN DIEGO, October 7, 2025 – ( Investorideas.com Newswire) Breaking Medical Tech News- Aethlon Medical, Inc. (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinic ...

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal first quarter ending June 30, 2025, on August 13, 2025, at 4:15 p.m. ET, followed by a conference call to discuss these results and recent corporate developments [1][2]. Financial Results Announcement - The financial results will be announced on August 13, 2025, at 4:15 p.m. ET [1]. - A conference call will take place on the same day at 4:30 p.m. ET to review the financial results and recent developments [2]. Conference Call Details - Interested parties can register for the conference call online, and registered participants will receive a dial-in number [2]. - For those without internet access, a toll-free number is available for participation [3]. Replay Information - A replay of the conference call will be available approximately one hour after the call and can be accessed until September 13, 2025 [4]. Product Overview - The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation [4]. - The device utilizes a novel platform that combines plasma separation, size exclusion, and affinity binding to target pathogenic elements in biological fluids [6]. Regulatory Designation - The Hemopurifier has received U.S. Food and Drug Administration Breakthrough Device Designation for treating advanced or metastatic cancer and life-threatening viruses [5]. Company Background - Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California, focusing on oncology and infectious disease [6].

Core Insights - Aethlon Medical, Inc. has made significant progress in its Hemopurifier® cancer trial, having treated three patients and received regulatory approval in India for a similar study [1][9][11] - The company has successfully reduced operating expenses by approximately 26% year-over-year, positioning itself for sustained focus on clinical and regulatory goals [14][16] - Preliminary data from the ongoing trials is expected to provide insights into the efficacy of the Hemopurifier in treating solid tumors and potentially Long COVID [4][10][13] Clinical Progress in Cancer Trial - The first three participants in the Hemopurifier trial completed treatment without complications, and safety follow-ups have been conducted [3][4] - An independent Data Safety Monitoring Board (DSMB) will review safety data and recommend advancement to the next treatment cohort [4] - The trial protocol has been amended to include patients receiving combination therapies with Pembrolizumab or Nivolumab, reflecting current treatment practices [5][6] Regulatory Approval India - Aethlon received approval from India's CDSCO to initiate a similar trial at Medanta Medicity Hospital, following necessary ethical clearances [9] Preclinical Study Supports Broader Applications - A preclinical study demonstrated that the Hemopurifier can remove 98.5% of platelet-derived extracellular vesicles (PD-EVs) from human plasma, indicating potential applications in various diseases [10][11] Scientific Collaboration in Long COVID Research - Aethlon is collaborating with UCSF to investigate the Hemopurifier's potential in treating Long COVID, with findings to be presented at an upcoming symposium [13] Operational Achievements - The company streamlined operations, resulting in a significant reduction in operating expenses, which decreased from approximately $12.6 million in fiscal 2024 to $9.3 million in fiscal 2025 [16][20] Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025 - As of March 31, 2025, Aethlon had a cash balance of approximately $5.5 million [15] - The operating loss for the fiscal year ended March 31, 2025, was $9.3 million, down from $12.6 million the previous year [20][32]

Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal fourth quarter ended March 31, 2025, on June 26, 2025, at 4:15 p.m. ET [1] Financial Results Announcement - The financial results will be followed by a conference call hosted by management on June 26, 2025, at 4:30 p.m. ET to discuss the results and recent corporate developments [2] - Interested parties can register for the conference call online, and registered participants will receive their dial-in number upon registration [2] Conference Call Details - For those without internet access, a toll-free participant dial-in number is available at 1-844-836-8741, with an international dial-in option at 1-412-317-5442 [3] - A replay of the call will be accessible approximately one hour after the call ends and will be available until July 26, 2025 [4] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful exosomes, which may contribute to immune suppression and cancer metastasis [5] - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5]

Core Insights - Aethlon Medical, Inc. is presenting research on the Hemopurifier® device's ability to bind extracellular vesicles (EVs) in Long COVID samples at an upcoming symposium [1][6] - Long COVID affects an estimated 44 to 48 million people in the U.S., with a significant economic burden projected at $2 billion for those experiencing symptoms for a year [2] - The Hemopurifier is designed to remove harmful EVs from the blood, which are implicated in the pathogenesis of Long COVID [4][8] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an investigational device aimed at treating cancer and life-threatening infectious diseases [8] - The Hemopurifier has shown efficacy in removing life-threatening viruses and harmful EVs in pre-clinical studies [8] - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [10] Research Details - The research presented will evaluate the binding of EVs from Long COVID patients to the Hemopurifier's affinity resin, which targets the sugar mannose [5][6] - The study involves collaboration with the University of California San Francisco Medical Center Long COVID clinic [5] - The poster presentation is scheduled for August 12, 2025, and will be available on Aethlon's corporate website afterward [6][7]

Core Insights - Aethlon Medical, Inc. announced the publication of a pre-clinical ex vivo study demonstrating the effectiveness of its Hemopurifier in removing platelet-derived extracellular vesicles (PD-EVs) from plasma, which supports ongoing oncology clinical trials in Australia [1][4][6] Group 1: Study Findings - The study showed a 98.5% removal of PD-EVs from 200 milliliters of healthy human plasma, simulating a 4-hour treatment session with the Hemopurifier [3][4] - The results indicate the potential of the Hemopurifier to address various diseases where PD-EVs are implicated, including cancer and other serious conditions [5][6] Group 2: Clinical Implications - The findings are expected to enhance the ongoing oncology clinical trial in Australia, where the focus will be on PD-EV removal in enrolled subjects [4][5] - The Hemopurifier is recognized as a Breakthrough Device by the FDA, aimed at treating advanced or metastatic cancer and life-threatening viral infections [6] Group 3: Future Directions - The company plans to submit the study findings for peer review and further investigate PD-EV removal in plasma samples from various diseases [5] - There is potential for the Hemopurifier to serve multiple therapeutic indications beyond oncology, suggesting a "pipeline within a device" concept [5]

Core Insights - Aethlon Medical's Hemopurifier® shows expanded therapeutic potential beyond virology and oncology, particularly in organ transplantation [1][2] - A preclinical study published in Transplant Immunology demonstrates the Hemopurifier's ability to remove extracellular vesicles (EVs) and microRNAs from discarded donor kidneys, which may improve kidney function post-transplant [1][2] - The company is currently focused on oncology trials in Australia and India, but the new data suggests a broader application for the Hemopurifier in organ preservation [2][3] Company Overview - Aethlon Medical is a therapeutic company developing the Hemopurifier, designed to combat cancer, life-threatening viral infections, and for organ transplantation [3] - The Hemopurifier has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [3] Research Findings - The preclinical study indicates significant reductions in EVs and microRNAs associated with renal dysfunction when using the Hemopurifier on perfusion fluid from discarded kidneys [2] - The study supports the hypothesis that EVs and microRNAs contribute to complications in kidney transplantation, such as delayed function and organ rejection [2] Future Directions - Further evaluation of the Hemopurifier's integration into machine perfusion circuits for discarded kidneys is necessary, with plans for clinical trials to assess its efficacy [2][3] - The technology could potentially enhance existing organ preservation methods, indicating a "pipeline within a device" for future therapeutic applications [2]